Filtered By:
Drug: Zetia
This page shows you your search results in order of relevance. This is page number 11.
Order by Relevance | Date
Total 236 results found since Jan 2013.
Searching for the ideal LDL cholesterol estimating formula
For long, low-density lipoprotein cholesterol (LDL-C) has been considered one of the major therapeutic targets for primary and secondary prevention in cardiovascular (CV) disease. Since more than two decades ago, pivotal trials have demonstrated that LDL-C lowering with statins translates into a log proportional reduction in a vast array of CV events (myocardial infarction, stroke, need for coronary or arterial revascularization), as well as mortality [1]. More recently, similar benefits have been observed with other LDL-C lowering therapies, such as ezetimibe [2] and proprotein covertase subtilisin kexin type 9 (PCSK-9) inhibitors [3].
Source: International Journal of Cardiology - March 9, 2021 Category: Cardiology Authors: Remo Holanda de Mendonca Furtado Tags: Editorial Source Type: research
Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Ezetimibe and PCSK9 monoclonal antibodies
Curr Med Chem. 2021 Feb 21. doi: 10.2174/0929867328666210222092628. Online ahead of print.ABSTRACTCardiovascular disease (CVD) remains the primary cause of global morbidity and mortality. CVD includes various life-threatening conditions such as myocardial infarction, stroke and peripheral arterial diseases. In this context, atherosclerosis continues to play the principal role in the pathogenesis of these conditions. Atherosclerosis emanates from a set of modifiable and non-modifiable risk factors that include age, male gender, family history, obesity, smoking, diabetes mellitus and hypertension. Recent evidence classifies ...
Source: Current Medicinal Chemistry - March 3, 2021 Category: Chemistry Authors: Adel Hajj Ali Nour Younis Rola Abdallah Farah Shaer Ali Dakroub Mohammed Ayoub Rabah Iratni Hadi Mohamad Yassine Kazem Zibara Alexander Orekhov Ahmed Fawzy El-Yazbi Ali Eid Source Type: research
Bempedoic acid: a cholesterol lowering agent with a novel mechanism of action
Expert Rev Clin Pharmacol. 2021 Mar 11. doi: 10.1080/17512433.2021.1901579. Online ahead of print.ABSTRACTINTRODUCTION: Dyslipidemia is a common condition that increases the risk of heart diseases and stroke. High levels of low-density lipoprotein-cholesterol (LDL-C) is correlated with a higher risk for heart disease. A drug class known as "statins" is the gold standard for LDL-C-lowering, but its use in some patients is limited by its adverse effects of myalgias and myopathies. Use of other LDL-C-lowering agents are frequently limited by cost and degree of efficacy. Additionally, many high-risk atherosclerotic cardiovascu...
Source: Expert Review of Clinical Pharmacology - March 11, 2021 Category: Drugs & Pharmacology Authors: Huyen Nguyen Ikenna Akamnonu Tianrui Yang Source Type: research
A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent
AbstractPatients with genetically associated elevated lipoprotein(a) [Lp(a)] levels are at greater risk for coronary artery disease, heart attack, stroke, and peripheral arterial disease. To date, there are no US FDA-approved drug therapies that are designed to target Lp(a) with the goal of lowering the Lp(a) level in patients who have increased risk. The American College of Cardiology (ACC) has provided guidelines on how to use traditional lipid profiles to assess the risk of atherosclerotic cardiovascular disease (ASCVD); however, even with the emergence of statin add-on therapies such as ezetimibe and proprotein convert...
Source: American Journal of Cardiovascular Drugs - September 7, 2021 Category: Cardiology Source Type: research
The Projected Impact of Population-Wide Achievement of LDL Cholesterol & lt;70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD
ConclusionA substantial number of recurrent ASCVD events could be averted over 10 years if all US adults with ASCVD achieved, and maintained, an LDL-C<70 mg/dL.
Source: Cardiovascular Drugs and Therapy - October 2, 2021 Category: Cardiology Source Type: research
Prevalence of and Factors Associated With the Prescription of Fibrates Among Patients Receiving Lipid-Lowering Drugs in Germany
Abstract:
Little recent data are available about the patterns of prescription for fibrates in patients followed in primary care practices. Therefore, the goal of this study was to analyze the prevalence of and the factors associated with the use of fibrates among patients receiving lipid-lowering drugs in Germany. The study included patients aged ≥18 years with at least 1 visit to 1 of 1070 general practices in Germany between January and December 2019. Lipid-lowering drugs included statins (without and with ezetimibe) and fibrates. The prevalence of the prescription of fibrates corresponded to the number of patients...
Source: Journal of Cardiovascular Pharmacology - December 1, 2021 Category: Cardiology Tags: Original Article Source Type: research
RSSDI consensus recommendations for dyslipidemia management in diabetes mellitus
AbstractDiabetic dyslipidemia is characterised by low HDL-C and high triglyceride levels. Unlike the Caucasian population, though LDL-C levels are not very high, there is a preponderance of more atherogenic small, dense LDL particles among Indians. Furthermore, apo B levels are elevated. This, unique ‘atherogenic dyslipidemia’, is frequently encountered in South Asians with diabetes. People with type 2 diabetes are considered to be at high risk for vascular events. Hence, irrespective of other risk factors such as age, male gender, hypertension, family history, smoking, obesity, and polycyst ic ovary syndrome in women,...
Source: International Journal of Diabetes in Developing Countries - April 7, 2022 Category: Endocrinology Source Type: research
Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis
Conclusions and RelevanceThis study identified the price at which inclisiran is cost effective for the US health system, at generally accepted willingness-to-pay thresholds.
Source: American Journal of Cardiovascular Drugs - May 21, 2022 Category: Cardiology Source Type: research
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
ConclusionsIcosapent ethyl is cost effective for primary and secondary cardiovascular prevention at an annual price of £2064 in the UK. For PCSK9 inhibitors, price discounts or prescription restrictions are necessary to achieve cost effectiveness.Graphical abstract
Source: Clinical Drug Investigation - July 11, 2022 Category: Drugs & Pharmacology Source Type: research
Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome
This study was a prospective, randomized controlled study. A total of 136 patients with extremely high-risk ACS with LDL-C ≥ 3.0 mmol/L after percutaneous coronary intervention (PCI) treatment were randomly assigned 1:1 to the control group (atorvastatin 40 mg/day and ezetimibe 10 mg/day) or the evolocumab group (evolocumab 140 mg every 2 weeks combined with atorvastatin 40 mg/day and ezetimibe 10 mg/day). We compared the blood lipid profiles, major adverse cardiovascular events (MACEs), and adverse reactions. MACEs included cardiogenic death, nonfatal myocardial infarction, nonfatal stroke, and readmission due to angina...
Source: International Heart Journal - July 13, 2022 Category: Cardiology Authors: Yan Hao Yu-Lin Yang Yong-Chao Wang Jian Li Source Type: research
